ANKETs target a tumor antigen, CD16, and the activation receptor NKp46 which was effective in a mouse model of lymphoma [173], ANKETs that also target IL-2R are currently under development (https://www.innate-pharma.com/science/our-nk-cell-engager-platform). The gene discussed is FCGR3A; the disease is neoplasm.